OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

OB-001Positive

AI Analysis

Summary

OncoBayes announced successful completion of preclinical work with OB-001, a drug candidate designed to address ADC resistance and TKI brain penetration in oncology. The company is advancing the program toward clinical development.

Outcome Details

Preclinical work completion announced

Importance:3/10

Sentiment:

0.60

oncologypreclinicalADC resistanceTKI brain penetrationunmet needs

Related Companies

$DFPH $BNN.DE

Read the original article

Published by PR Newswire Clinical Trials on October 7, 2026 6:00 AM

Read Original